Company intelligence / Profile preview

Heights

London, England, United Kingdomhoustonisd.org ↗

Ownership: Private
Development stage: NDA

Overview

Commercially available supplements with positive consumer feedback. Claims are based on scientific literature review but no clinical trial data disclosed. Recently launched facility supporting R&D projects in alternative proteins and sustainable foods. No direct clinical results as it’s an infrastructure/platform provider.

Therapeutic areas: GastroenterologyPsychiatryNeurologyOther
Modalities: Nutritional supplements (vitamins/minerals/probiotics/magnesium)Alternative proteins via fermentation and bioprocessing technologies
Industry: Academic Hospital/University/Research

Drug pipeline

3 assets

ZEPIZURE

NDA

Indications: Epilepsy

2 more assets in the full pipeline.

Request access →

Partnerships

Lund University/Tetra Pak/Vinnova/Future by Lund

Beyond the preview

Go deeper on Heights.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heights.

Explore the full profile